Editing VAL-083 (Dianhydrogalactitol)
From Glioblastoma Treatments
Revision as of 20:39, 30 March 2024 by Lazy (talk | contribs) (Created page with "{{TreatmentInfo |drug_name=VAL-083 (Dianhydrogalactitol) |FDA_approval=Approved in China for CML and lung cancer; not yet approved outside of China for GBM |used_for=Recurrent Glioblastoma Multiforme (GBM) with unmethylated MGMT promoter |clinical_trial_phase=Phase 2 (ongoing evaluation in GBM AGILE for various GBM subtypes) |common_side_effects=Myelosuppression, including neutropenia and lymphopenia; some instances of serious adverse events possibly related to VAL-083 |...")
Warning: You are editing an out-of-date revision of this page.
If you publish it, any changes made since this revision will be lost.
Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.